SCHEMBL4121706

SCHEMBL4121706

Cc1c(Sc2ccc(Cl)cc2)cc(C(C)(C)C)c(O)c1C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLRA3 O75311 1/20 0.49
GLRB P48167 1/20 0.49
RHEB Q15382 4/20 0.44
CTRC Q99895 1/20 0.36
LMNA P02545 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
POLB P06746 1/20 0.36
BCL2L1 Q07817 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
XDH P47989 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
DHODH Q02127 1/20 0.35
GAA P10253 1/20 0.35
IGFBP3 P17936 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4128339 0.90 GLRA3 (0.51) GLRA3GLRBLMNAKDM4EALDH1A1
SCHEMBL4121770 0.88 GLRA3 (0.50) GLRA3GLRBRHEBALDH1A1MAPT
SCHEMBL4129099 0.88 GLRA3 (0.53) GLRA3GLRBALDH1A1MAPTHPGD
SCHEMBL4127647 0.88 GLRA3 (0.47) GLRA3GLRBRHEBKDM4EALDH1A1
SCHEMBL4123084 0.87 GLRA3 (0.49) GLRA3GLRBRHEBALDH1A1MAPT
SCHEMBL4126598 0.87 GLRA3 (0.43) GLRA3GLRBRHEBLMNAMEN1
SCHEMBL4117087 0.85 GLRA3 (0.47) GLRA3GLRBRHEBKDM4EALDH1A1
SCHEMBL4115630 0.85 GLRA3 (0.47) GLRA3GLRBALDH1A1MEN1KMT2A
SCHEMBL4113656 0.85 GLRA3 (0.47) GLRA3GLRBLMNAKDM4EALDH1A1
SCHEMBL4129271 0.85 GLRA3 (0.47) GLRA3GLRBLMNAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090192190-A1 Benzoic Acid Derivatives that are Modulators or Agonists of GlyR ASTRAZENECA AB (SE) 2009-07-30 US claimed
EP-1890993-A2 BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR ANTAGONISTS OF GLYR AstraZeneca AB (SE) 2008-02-27 EP claimed
WO-2006121390-A2 BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR AGONISTS OF GLYR ASTRAZENECA AB (SE) 2006-11-16 WO claimed
US-20090192190-A1 Benzoic Acid Derivatives that are Modulators or Agonists of GlyR ASTRAZENECA AB (SE) 2009-07-30 US disclosed
EP-1890993-A2 BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR ANTAGONISTS OF GLYR AstraZeneca AB (SE) 2008-02-27 EP disclosed
WO-2006121390-A2 BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR AGONISTS OF GLYR ASTRAZENECA AB (SE) 2006-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192190-A1 Benzoic Acid Derivatives that are Modulators or Agonists of GlyR GLRA1, GLRB, GPBAR1 GLRA3 6/4885GLRB 2/4885RHEB 3735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.